Organization | National Center for Tuberculosis and Lung Diseases, Georgia

National Center for Tuberculosis and Lung Diseases, Georgia Report issue

Government Phase 2 Phase 3

Organization Overview

First Clinical Trial

2016

NCT02781909

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Alternative names

National Center for Tuberculosis and Lung Diseases (NCTLD) | National Center for Tuberculosis and Lung Diseases of Georgia (NCTLD) | National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia

Active Ingredients

Drugs in Phase 3 Trials (8)

bedaquiline (sirturo) (1 trial)

clofazimine (lamprene) (1 trial)

levofloxacin (levaquin) (1 trial)

linezolid (zyvox) (1 trial)

moxifloxacin (avelox) (1 trial)

nyaditum resae (1 trial)

opc-67683 (1 trial)

pyrazinamide (Aldinamide) (1 trial)

Drugs in Phase 2 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

ibuprofen (motrin) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Bacterial Infections (Phase 3)

Latent Tuberculosis (Phase 2)

Tuberculosis (Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 10